Cocrystal Pharma Extends Drug Discovery Collaboration with HitGen and InterX
March 10, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash, March 10, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Participate in the Virtual 33rd Annual Roth Conference
March 09, 2021 07:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 09, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference [UPDATED]
March 02, 2021 11:28 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at the H.C. Wainwright Global Life Sciences Virtual Conference
March 02, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., March 02, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Presentation at the reimagine Health Research Symposium Features Overview of Platform Technology and Four Antiviral Case Studies
January 21, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 21, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Announces Further Development of Influenza A/B Antiviral Compounds by Merck under Exclusive Worldwide License and Collaboration Agreement
January 19, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
Program advances within the agreement’s initial two-year timeframe BOTHELL, Wash., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a...
Cocrystal to Present at the 3rd Annual reimagine Health Research Symposium
January 14, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 14, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at Virtual NobleCon17 Conference on January 19, 2021
January 12, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 12, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma to Present at H.C. Wainwright Virtual BioConnect Conference
January 05, 2021 08:00 ET
|
Cocrystal Pharma, Inc.
BOTHELL, Wash., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP), (“Cocrystal” or the “Company”), a clinical-stage biotechnology company discovering and developing novel...
Cocrystal Pharma Selects Lead Compound for Further Development Against Coronaviruses
December 22, 2020 08:30 ET
|
Cocrystal Pharma, Inc.
CDI-45205 holds potential as a therapeutic and as a prophylactic to protect against coronavirus transmission, including SARS-CoV-2 BOTHELL, Wash., Dec. 22, 2020 (GLOBE NEWSWIRE) -- Cocrystal...